Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Lucitanib
Другие языки:

    Lucitanib

    Подписчиков: 0, рейтинг: 0
    Lucitanib
    Lucitanib.svg
    Clinical data
    Other names CO-3810, E-3810
    Routes of
    administration    		 By mouth
    ATC code
    • None
    Legal status
    Legal status
    • Investigational
    Pharmacokinetic data
    Elimination half-life 31–40 hrs
    Identifiers
    • 6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C26H25N3O4
    Molar mass 443.503 g·mol−1
    3D model (JSmol)
    • CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
    • InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)
    • Key:CUDVHEFYRIWYQD-UHFFFAOYSA-N

    Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.


    Новое сообщение